Klogene Therapeutics, Inc.
http://www.klogene.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Klogene Therapeutics, Inc.
Deal Watch: Lilly Will Take Over Beam’s Rights To Verve Cardiovascular Assets
Lilly looks To Elektrofi for help on subcutaneous injectable therapies, while NAYA will merge with INVO and acquire two antibodies from Cytovia. Plus deals involving Hummingbird/Endeavor, Basilea/Gravitas/Intron, Lilly/Mablink and Sotio/Synaffix.
Tech Transfer Roundup: Arrakis Gets Penn IP Toward Small Molecule RNA Therapies
Canaan Partners-backed biotech will investigate the therapeutic potential of three-way junctions in folded RNA. UC Berkeley and Duke sign separate license agreements related to CRISPR gene-editing technology.
Execs On The Move, July-August 2014
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
Deals Of The Week: Pfizer/NextWave, Genzyme/Alnylam, AstraZeneca/Ironwood
Two Western big pharmas struck back-to-back deals this week with two U.S. biopharmas and will bring their innovative drugs to Asia without a local partner. The details of the deals are different, but both signal a willingness on the part of biopharmas to partner with experienced, feet-on-the-ground Western companies as a route into emerging Asian markets, though they’ll still need to find a local partner down the road.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- Kogenix Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice